Bechtel Medical’s Wound VOX, a system that integrates negative pressure wound therapy and topical oxygen therapy has secured clearance from the US Food and Drug Administration (FDA).
The FDA clearance makes Wound Vox the first combined negative pressure and topical oxygen system cleared via the agency’s 510(k) pathway. Bechtel Medical now intends to initiate a limited commercial rollout of the system in December 2026.
The company engineered Wound Vox to run in three operational modes: continuous NPWT, intermittent NPWT, and intermittent NPWT combined with adjunctive topical oxygen therapy (TOT).